123sek
3,4 %
Date:2025-05-14Time:17:29:45Latest report:Q1-2025List:First NorthTicker:IVACC
Market Cap:419 msekEnterprise Value:203 msekNet Sales:14,0 msekEarnings:-71,3 msekEmployees:0ISIN:SE0009607252

Ratios

10-year key figure history for Intervacc turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Intervacc with index and moving average MA50 and MA200.

Stockprice:1,23
MA50:1,02
MA200:2,09
Price/MA200:-41,2 %
RSI (14):65,7
Price/MA50:20,2 %

Description

Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.

Biotechnology